Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
| Image |  |
|---|---|
| Description | scientific article published on 23 January 2015 |
| Author/s |
author: Peter Vuylsteke Jacques De Greve |
| Publication date | January 23, 2015 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |